OverviewSuggest Edit

Trevi Therapeutics is a drug development company focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus. 

TypePublic
Founded2011
HQNew Haven, US
Websitetrevitherapeutics.com

Latest Updates

Employees (est.) (Dec 2019)17(+14%)
Revenue (FY, 2018)$14.1 M(+131%)
Share Price (Jul 2020)$5.5
Cybersecurity ratingAMore

Key People/Management at Trevi Therapeutics

Jennifer Good

Jennifer Good

Co-Founder, President and CEO, Director
Thomas Sciascia

Thomas Sciascia

Co-Founder, Chief Medical Officer
Helena Brett-Smith

Helena Brett-Smith

Chief Development Officer
Yann Mazabraud

Yann Mazabraud

Chief Commercial Officer and Head of International
Christopher J. Seiter

Christopher J. Seiter

Chief Financial Officer
David Meeker

David Meeker

Chairman
Show more

Trevi Therapeutics Office Locations

Trevi Therapeutics has an office in New Haven
New Haven, US (HQ)
195 Church St
Show all (1)

Trevi Therapeutics Financials and Metrics

Trevi Therapeutics Revenue

Trevi Therapeutics's revenue was reported to be $14.07 m in FY, 2018 which is a 130.9% increase from the previous period.
USD

Net income (Q1, 2020)

(8.5m)

EBIT (Q1, 2020)

(8.6m)

Market capitalization (9-Jul-2020)

97.6m

Closing stock price (9-Jul-2020)

5.5

Cash (31-Mar-2020)

52.6m

EV

45.3m
Trevi Therapeutics's current market capitalization is $97.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

6.1m14.1m

Revenue growth, %

131%

General and administrative expense

2.1m4.3m7.3m

R&D expense

6.1m14.1m19.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

General and administrative expense

1.5m1.9m2.0m2.6m

R&D expense

3.3m5.5m5.7m6.0m

Operating expense total

4.8m7.4m7.7m8.6m

EBIT

(4.8m)(7.4m)(7.6m)(8.6m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

22.0m7.2m57.3m

Prepaid Expenses

93.0k1.4m1.7m

Current Assets

22.2m8.8m59.6m

PP&E

14.0k149.0k118.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

12.9m71.4m63.5m52.6m

Prepaid Expenses

1.7m3.0m1.8m1.1m

Current Assets

14.8m74.6m65.5m53.8m

PP&E

149.0k139.0k128.0k107.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(12.9m)(20.5m)(26.0m)

Depreciation and Amortization

4.0k23.0k39.0k

Accounts Payable

92.0k66.0k777.0k

Cash From Operating Activities

(8.0m)(18.3m)(23.1m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(4.8m)(12.1m)(19.5m)(8.5m)

Depreciation and Amortization

9.0k19.0k30.0k10.0k

Accounts Payable

(185.0k)1.7m(332.0k)594.0k

Cash From Operating Activities

(4.1m)(9.2m)(16.9m)(4.7m)
USDFY, 2017

Revenue/Employee

746.3k

Debt/Equity

-0.1 x

Debt/Assets

0.2 x

Financial Leverage

-0.3 x
Show all financial metrics

Trevi Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Trevi Therapeutics Limited

Trevi Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Trevi Therapeutics Online and Social Media Presence

Embed Graph

Trevi Therapeutics News and Updates

Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments

Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement

Trevi Therapeutics Announces Pricing of Initial Public Offering

NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public…

Trevi Therapeutics to offer 6.7 million shares in planned IPO priced at $14 to $16 each

Trevi Therapeutics set terms for its planned initial public offering on Monday, saying it plans to offer 4.7 million shares priced at $14 to $16 each to raise up to $75.2 million. The biotech, which is focused on developing treatments for neurologically mediated conditions including Parkinson's dise…

Trevi Therapeutics Frequently Asked Questions

  • When was Trevi Therapeutics founded?

    Trevi Therapeutics was founded in 2011.

  • Who are Trevi Therapeutics key executives?

    Trevi Therapeutics's key executives are Jennifer Good, Thomas Sciascia and Helena Brett-Smith.

  • How many employees does Trevi Therapeutics have?

    Trevi Therapeutics has 17 employees.

  • Who are Trevi Therapeutics competitors?

    Competitors of Trevi Therapeutics include ITBMed, BridgeBio and Cantabio Pharmaceuticals.

  • Where is Trevi Therapeutics headquarters?

    Trevi Therapeutics headquarters is located at 195 Church St, New Haven.

  • Where are Trevi Therapeutics offices?

    Trevi Therapeutics has an office in New Haven.

  • How many offices does Trevi Therapeutics have?

    Trevi Therapeutics has 1 office.